
|Videos|June 5, 2017
Dr. Sharman on the Phase III Results of the GENUINE Study in CLL
Author(s)Jeff Sharman, MD
Jeff Sharman, MD, medical director, Hematology Research, The US Oncology Network, discusses the phase III findings of the GENUINE study, the combination of ublituximab (TG-1101) and ibrutinib (Imbruvica) for patients with previously treated high-risk chronic lymphocytic leukemia (CLL).
Advertisement
Jeff Sharman, MD, medical director, Hematology Research, The US Oncology Network, discusses the phase III findings of the GENUINE study, the combination of ublituximab (TG-1101) and ibrutinib (Imbruvica) for patients with previously treated high-risk chronic lymphocytic leukemia (CLL).
<<<
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
3
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
4
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
5



































